Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(67%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
3
100%

Phase Distribution

3

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Completed(1)

Detailed Status

Active, not recruiting1
Recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 13 (100.0%)

Trials by Status

active_not_recruiting133%
recruiting133%
completed133%

Recent Activity

2 active trials
Showing 3 of 3
active_not_recruitingphase_1

Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)

NCT03393884
recruitingphase_1

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT05739981
completedphase_1

Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer

NCT02480374

Clinical Trials (3)

Showing 3 of 3 trials
NCT03393884Phase 1

Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)

Active Not Recruiting
NCT05739981Phase 1

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Recruiting
NCT02480374Phase 1

Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3